Hydroxychloroquine (HCQ) is generally considered safe in pregnancy for the treatment of rheumatic conditions, but studies have been too small to evaluate teratogenicity. Quantifying the risk of congenital malformations associated with early pregnancy exposure to HCQ is important both in the context of its ongoing use for rheumatological disorders as well as its potential future use for COVID-19 prophylaxis, for which a number of clinical trials are ongoing despite initial trials for COVID-19 treatment having been negative.
There has been increasing research momentum to identify new therapeutic agents for preeclampsia. Most have adopted the pragmatic strategy of repurposing drugs. Pravastatin has been the most studied and there is significant preclinical and early phase trial evidence suggesting it may have therapeutic activity. Further large clinical trials evaluating whether pravastatin can prevent preeclampsia are planned, or ongoing. Other drugs or treatment approaches that have transitioned to human trials (ranging from single arm to phase III trials) includes esomeprazole, metformin, sulfasalazine, folate, nitric oxide donors (such as L-Arginine), apheresis, recombinant antithrombin III, digoxin immune Fab; and antioxidants such as melatonin.
Following strong evidence and major organizations recommending salpingectomy over tubal ligation, we sought to perform a systematic review and meta-analysis comparing the intraoperative attributes and complication rates associated with these two procedures.
A growing literature suggest that minority races, particularly Black women, have lower probability of live birth and higher risk of perinatal complications after autologous ART. However, questions still remain as to whether these racial disparities have arisen due to associations between race and oocyte/embryo quality, the uterine environment, or a combination of the two. Oocyte donation ART represents a unique approach to examine this question.
In June 2013, Ontario Health – Cancer Care Ontario (CCO), the agency responsible for advancing cancer care in Ontario, Canada, published practice guidelines recommending that Gynaecologic Oncologists (GOs) at tertiary care centers manage the treatment of patients with high-grade endometrial cancers. This study examines the effects of this regionalization of care on patient outcomes.